...
首页> 外文期刊>Consultant >Patients With Resistant Hypertension: What's the Best Pharmacologic Strategy?
【24h】

Patients With Resistant Hypertension: What's the Best Pharmacologic Strategy?

机译:

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

In last issue's column, we discussed the case of JG, a patient with newly diagnosed hypertension (HTN). Upon diagnosis, consistent with national guidelines (ie, the Eighth Joint National Committee), JG was started on a thiazide diuretic, namely chlorthalidone. Over the next several months, despite continual efforts to reduce his weight, control his salt intake, and increase his activity level, JG's blood pressure (BP) remained elevated. Accordingly, he was started on amlodipine, which was titrated to 10 mg daily, and lisinopril, which was titrated to 40 mg daily. Despite both the pharmacologic and nonpharmaco-logic efforts, JG's BP remained elevated at 155/91 mm Hg. What is the next best step for JG to control his BP?

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号